Table 3.
Median IgG responses (MFI-bg) to Bm14, Bm33, PTP3, and MSP-119 from treatment groups in 148 children at time points A, B, and C, Haiti*
| Observation | Treatment group (no.) | |||
|---|---|---|---|---|
| Placebo (41) | ALB (36) | DEC (43) | DEC/ALB (28) | |
| Pretreatment (time point A) | ||||
| Bm14/IgG | 20,893 | 25,333 | 6,755 | 16,747 |
| Bm33/IgG | 15,905 | 20,596 | 15,555 | 20,991 |
| PTP3/IgG | 46 | 62 | 51 | 37 |
| MSP-119/IgG | 8 | 10 | 12 | 10 |
| Three months post-treatment (time point B) | ||||
| Bm14/IgG | 23,467 | 17,560 | 2,099† | 4,996† |
| Bm33/IgG | 16,077 | 18,325 | 8,894† | 8,587† |
| PTP3/IgG | 36 | 59 | 41 | 33 |
| MSP-119/IgG | 8 | 10 | 9‡ | 7 |
| Six months post-treatment (time point C) | ||||
| Bm14/IgG | 24,135 | 16,600 | 1,650†§ | 1,508† |
| Bm33/IgG | 13,000 | 16,882 | 5,166†¶# | 7,533†¶ |
| PTP3/IgG | 49 | 55 | 51 | 31 |
| MSP-119/IgG | 7 | 10 | 12 | 8 |
MFI = median fluorescence intensity; bg = background; ALB = albendazole; DEC = diethylcarbamazine.
Median values (MFI-bg, IgG responses) significantly lower (P < 0.005) compared with time point A in same treatment group (by Tukey test).
Median values (MFI-bg, IgG responses) significantly lower (P = 0.031) compared with time point A in same treatment group (by Tukey test).
Median values (MFI-bg, IgG responses) significantly lower (P < 0.005) compared with albendazole and placebo children at the same time point (by Kruskal-Wallis test).
Median values (MFI-bg, IgG responses) significantly lower (P < 0.001) compared with albendazole children at the same time point (by Kruskal-Wallis test).
Median values (MFI-bg, IgG responses) significantly lower (P < 0.001) compared with placebo children at the same time point (by Kruskal-Wallis test).